Bevirimat: A novel maturation inhibitor for the treatment of HIV-1 infection

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 3, 2008, Pages 107-113

  Martin, David E ^a   Salzwedel, Karl ^a   Allaway, Graham P ^a  

^a Panacos Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BEVIRIMAT; GAG PROTEIN; NUCLEOSIDE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; GLUCURONIDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS PARTICLE; VIRUS RESISTANCE;

EID: 56249119547     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020801900301     Document Type: Review

References (43)

1. Maplanka C. AIDS: is there an answer to the global pandemic? The immune system in HIV infection and control. Viral Immunol 2007; 20:331-342.
2. Montaner JS. Challenges of the unmet needs in the treatment-experienced patient. AIDS Read 2003; 13 Suppl 6:S5-S9.
3. Jain R, Clark NM, Diaz-Linares M, Grim SA. Limitations of current antiretroviral agents and opportunities for development. Curr Pharm Des 2006; 12:1065-1074.
4. Anderson AM, Bartlett JA. Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. Curr HIV/AIDS Rep 2006; 3:79-85.
5. Gallant JE. Approach to the treatment-experienced patient. Curr HIV/ AIDS Rep 2005; 2:83-89.
6. Harris M, Montaner JS. Management of HIV-infected patients with multidrug-resistant virus. Curr HIV/AIDS Rep 2004; 1:116-121.
7. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2004; 362:2002-2011.
8. Descamps D, Chaix ML, André P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-552.
9. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
10. Oette M, Kaiser R, Daumer M, et al. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 2004; 9:273-278.
11. Jayaraman GC, Archibald CP, Kim J, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006; 42:86-90.
12. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41:1316-1323.
13. Hanson K, Hicks C. New antiretroviral drugs. Curr HIV/AIDS Rep 2006; 3:93-101.
14. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11:1805-1843.
15. Flexner C. HIV drug development: the next 25 years. Nature Rev Drug Discov 2007; 6:959-966.
16. Hubatsch I, Lazorova L, Vahlne A, Artursson P. Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium. Antimicrob Agents Chemother 2005; 49:1087-1092.
17. Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 2003; 100:13555-13560.
18. Sakalian M, McMurtrey CP, Deeg FJ, et al. 3-O-(3′,3′-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 gag precursor assembled in vitro. J Virol 2006; 80:5716-5722.
19. Zhou J, Yuan X, Dismuke D, et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004; 78:922-929.
20. Reeves JD, Piefer AJ. Emerging drug targets for antiretroviral therapy. Drugs 2005; 65:1747-1766.
21. Li F, Zoumplis D, Matallana C, et al. Determinants of activity of the HIV-1 maturation inhibitor PA-457 map to the N-terminal half of the Gag SP1 domain. Cold Spring Harbor Laboratory Meeting on Retroviruses. 25-30 May 2004, Cold Spring Harbor, NY, USA. Session 14.
22. Fujioka T, Kashiwada Y, Kilkuskie RE, et al. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 1994; 57:243-247.
23. Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, Lee KH. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 1996; 39:1016-1017.
24. Li F, Zoumplis D, Matallana C, et al. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 2006; 356:217-224.
25. Stoddart CA, Joshi P, Sloan B, et al. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS ONE 2007; 2:e1251.
26. Zhou J, Chen CH, Aiken C. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3′,3′-dimethylsuccinyl}-betulinic acid. Retrovirology 2004; 1:15.
27. Adamson CS, Ablan SD, Boeras I, et al. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat). J Virol 2006; 80:10957-10971.
28. Malet I, Wirden M, Derache A, et al. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS 2007; 21:871-873.
29. Adamson CS, Salzwedel K, Golia-Gaur R, et al. Viral resistance to PA-457, a novel inhibitor of HIV-1 maturation. Cold Spring Harbor Laboratory Meeting on Retroviruses. 24-29 May 2005, Cold Spring Harbor, NY, USA. Session 3.
30. Kilgore N, Reddick M, Zuiderhof M, et al. The first-in-class maturation inhibitor, PA-457, is a potent inhibitor of HIV-1 drug-resistant isolates and acts synergistically with approved HIV drugs in vitro. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 509.
31. 14C-bevirimat in rats and marmosets. 4th International AIDS Society Conference. 22-25 July 2007, Sydney, Australia. Abstract WEPEA090.
32. Martin DE, Blum R, Wilton J, et al. Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 2007; 51:3063-3066.
33. Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple dose pharmacokinetics and safety of bevirimat, a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Clin Pharmacokinet 2007; 46:589-598.
34. Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007; 51:3574-3581.
35. Martin DE, Ballow CH, Blum R, Doto J, Wild CT, Allaway GP. The safety, tolerability and pharmacokinetics of multiple oral doses of PA-457, a first-in-class HIV maturation inhibitor, in healthy volunteers. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract 551.
36. Martin DE, Galbraith H, Schettler J, et al. Minimal effect of ritonavir (RTV) on the pharmacokinetics of bevirimat (BVM) in healthy volunteers. 4th International AIDS Society Conference. 22-25 July 2007, Sydney, Australia. Abstract WEPEB015.
37. Martin DE, Gailbraith H, Schettler J, Ellis C, Doto J. Lack of a PK/PD interaction between bevirimat (PA-457) and atazanavir (ATV) in healthy volunteers. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2006, San Francisco, CA, USA. Abstract A/377.
38. Martin DE, Smith P, Goila-Gaur R, et al. Determinants of activity, in vitro metabolism and in vivo disposition of the novel maturation inhibitor PA-457. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 545.
39. Wen Z, Stern ST, Martin DE, Lee KH, Smith PC. Structural characterization of anti-HIV drug candidate PA-457 and its acyl glucuronide metabolites in rat bile and human urine and evaluation of in vitro stability by liquid chromatography-electrospray ionization-mass spectrometry. Drug Metab Dispos 2006; 34:1436-1442.
40. Wen Z, Martin DE, Bullock P, Lee KH, Smith PC. Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences. Drug Metab Dispos 2007; 35:440-448.
41. Beatty G, Jacobson J, Lalezari J, et al. Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 16-19 December 2005, Washington, DC, USA. Abstract H-416d.
42. Björndal A, Deng H, Jansson M, et al. Co-receptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71:7478-7487.
43. McCallister S, Doto J, Allaway G, et al. Multiple dosing of the novel HIV-1 maturation inhibitor bevirimat (BVM): aggregate adverse event (AE) and laboratory data from four short-term studies. 4th International AIDS Society Conference. 22-25 July 2007, Sydney, Australia. Abstract WEPEA110.